MS-444

CAS No. 150045-18-4

MS-444( —— )

Catalog No. M33436 CAS No. 150045-18-4

MS-444 (BE-34776) is a smooth muscle myosin light chain kinase (MLCK) and HuR inhibitor with antitumor activity for triple-negative breast and colorectal cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 759 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MS-444
  • Note
    Research use only, not for human use.
  • Brief Description
    MS-444 (BE-34776) is a smooth muscle myosin light chain kinase (MLCK) and HuR inhibitor with antitumor activity for triple-negative breast and colorectal cancer.
  • Description
    MS-444 inhibits the activity of purified smooth muscle myosin light chain kinase (MLCK) with an IC50 value of 10 μM.
  • In Vitro
    MS-444 is a small molecule RNA-binding protein HuR (ELAVL1) inhibitor. Colorectal cancer (CRC) cells that display HuR overexpression are treated with MS-444 (1-100 μM) for 48 hr with IC50s of 10.98±1.76 μM, 12.84±2.10 μM, 5.60±0.90 μM, 14.21±2.11 μM, and 10.98±1.24 μM for HCT116, HCA-7, RKO, HT-29, and SW480 cells, respectively. Growth inhibition is observed in all CRC lines with IC50 values ranging from 5.60 μM to 14.21 μM with observable effects seen at 10 μM MS-444. Contrasting effects are observed using non-transformed small intestinal (RIE-1 (IC50=40.70±3.53 μM)) and colonic (YAMC (IC50=28.16±3.23 μM)) epithelial cells. Both cell types display properties of normal intestinal epithelial cells and are proficient in 3′UTR AU-rich elements (ARE)-mRNA decay. Both non-transformed cell lines are ~3- to 4-fold less responsive to MS-444-mediated growth inhibition, with IC50 values of 40.70 μM and 28.16 μM (P<0.05).
  • In Vivo
    To test the effects of MS-444 on CRC cell growth in vivo, mice bearing HCT116 cell xenografts receive IP injections of MS-444 (25 mg/kg bw) or vehicle every 48 hr. Over the experiment course, mice do not display any adverse effects and maintained similar weights. Anti-tumor effects of MS-444 are observed with approximately 1.7-fold reduction in tumor size. Mice treated with MS-444 show a marked 2- to 3-fold decrease inmicrovessel density (MVD), indicating the anti-angiogenic potential of MS-444.
  • Synonyms
    ——
  • Pathway
    Cytoskeleton/Cell Adhesion Molecules
  • Target
    Myosin
  • Recptor
    Myosin | Serine/threonin kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    150045-18-4
  • Formula Weight
    230.22
  • Molecular Formula
    C13H10O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (217.18 mM; Ultrasonic )1-Methyl-2-pyrrolidinone : 20 mg/mL (86.87 mM; Ultrasonic)
  • SMILES
    O=C1C=2C(O)=CC=C(O)C2CC3=COC(=C13)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Satoshi Nakanishi. et al. MS-444, a new inhibitor of myosin light chain kinase from Micromonosporasp.KY7123. The Journal Of Antibiotics. 1995,48(9):948-951.?
molnova catalog
related products
  • BTS

    A highly specific myosin II ATPase inhibitor; inhibits the Ca2+-stimulated S1 ATPase, and reversibly blocked gliding motility.

  • Danicamtiv

    Danicamtiv is an inotropic agent and it also is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.

  • Myokinasib

    Myokinasib is a mixed-type, selective inhibitor of Myosin Light Chain Kinase 1 (MLCK1) with IC50 of 7.9 uM.